Cargando…

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

BACKGROUND: Levodopa remains the most effective drug in the treatment of Parkinson’s disease. However, long-term administration of levodopa induces motor complications, such as levodopa-induced dyskinesia. The mechanisms underlying levodopa-induced dyskinesia are not fully understood. METHODS: In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xinxin, Zheng, Ruiyuan, Cai, Yunpeng, Liao, Meiling, Yuan, Weien, Liu, Zhenguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356186/ https://www.ncbi.nlm.nih.gov/pubmed/22619544 http://dx.doi.org/10.2147/IJN.S30463

Ejemplares similares

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease
por: Wan, Ying, et al.
Publicado: (2017)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Yang, Xinxin, et al.
Publicado: (2013)

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®
por: Gasser, Urs E, et al.
Publicado: (2013)

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats
por: Alirezaei, Masoud
Publicado: (2015)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Involvement of Autophagy in Levodopa‐Induced Dyskinesia
por: Feyder, Michael, et al.
Publicado: (2021)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
por: Zheng, Chang-Qing, et al.
Publicado: (2021)

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
por: Xie, Cheng-long, et al.
Publicado: (2014)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Levodopa-induced belly dancer's dyskinesia: Case report
por: Cavalcante-Filho, José Renan Miranda, et al.
Publicado: (2020)

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
por: Steece‐Collier, Kathy, et al.
Publicado: (2019)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Cui, Guiyun, et al.
Publicado: (2013)

Electrochemical Sensor Based on Multi-Walled Carbon Nanotubes and N-Doped TiO(2) Nanoparticles for Voltametric Simultaneous Determination of Benserazide and Levodopa
por: da Silva, Elisangela Pacheco, et al.
Publicado: (2022)

Basal Ganglia Circuits Underlying the Pathophysiology of Levodopa-Induced Dyskinesia
por: Barroso-Chinea, Pedro, et al.
Publicado: (2010)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Cerebellum in Levodopa-Induced Dyskinesias: The Unusual Suspect in the Motor Network
por: Kishore, Asha, et al.
Publicado: (2014)

Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management
por: Pandey, Sanjay, et al.
Publicado: (2017)

Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia
por: Martini, Michael L., et al.
Publicado: (2019)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
por: Windolf, Hellen, et al.
Publicado: (2022)

Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease
por: Yang, Yifan, et al.
Publicado: (2023)

Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
por: Shi, Hongjuan, et al.
Publicado: (2015)

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes
por: Pagliaroli, Luca, et al.
Publicado: (2021)

Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation
por: Zhang, Fanshi, et al.
Publicado: (2023)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_661oa2gpk6j1bdm5logvj8mj39